How Do You Choose a Second-Line Treatment Option for Depression?

被引:1
|
作者
Weisler, Richard H. [1 ,2 ]
机构
[1] Univ N Carolina, Dept Psychiat, Chapel Hill, NC USA
[2] Duke Univ, Dept Psychiat, Durham, NC 27706 USA
关键词
ANTIDEPRESSANT THERAPY; POSTSTROKE DEPRESSION; MYOCARDIAL-INFARCTION; SEXUAL DYSFUNCTION; CARDIAC MORTALITY; SSRIS; RISK; AUGMENTATION; MEDICATION; BUPROPION;
D O I
10.4088/JCP.9104su1c.04
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
A majority of patients with major depression do not remit or adequately respond to initial antidepressant therapy. When response is insufficient, a diagnosis of depression and any comorbidities should be confirmed, treatment adherence should be established, and antidepressant dosages should be optimized as tolerated. If response is still insufficient, then implementing second-line treatment strategies is warranted. Second-line strategies of switching to or combining/augmenting the initial agent with one of a variety of antidepressant medications and/or psychotherapies improves remission rates, although no single approach or agent has demonstrated clear superiority over any other. Second-line treatment selections should be driven by safety considerations, patients' symptom profiles, and patient preference. Comorbid medical conditions, especially cardiac and cerebrovascular complications, and potential drug-drug interactions should be considered when making treatment decisions. (J Clin Psychiatry 2010;71[suppl 1]:21-26)
引用
收藏
页码:21 / 26
页数:6
相关论文
共 50 条
  • [31] Second-line treatment for chronic tuberculosis
    Mohapatra, PR
    Janmeja, AK
    Saini, V
    Das, SK
    Deb, A
    LANCET, 2002, 360 (9343): : 1430 - 1430
  • [32] Second-Line Treatment of Advanced Gastric Cancer: Where Do We Stand?
    Mahipal, Amit
    Choi, Minsig
    Kim, Richard
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2015, 13 (10): : 1281 - 1292
  • [33] After standard treatment, do the second-line and third-line treatments make sense?
    Sabbatini, R
    Maur, M
    Mucciarini, C
    Conte, PF
    TUMORI, 2003, : S33 - S34
  • [34] Only a second line treatment option
    Haferkamp, Axel
    AKTUELLE UROLOGIE, 2006, 37 (05) : 318 - +
  • [35] Tivantinib, a new option for second-line treatment of advanced hepatocellular carcinoma? The experience of Italian centers
    Rimassa, Lorenza
    Santoro, Armando
    Daniele, Bruno
    Germano, Domenico
    Gasbarrini, Antonio
    Salvagni, Stefania
    Masi, Gianluca
    Abbadessa, Giovanni
    Lamar, Maria
    Goldberg, Terri
    Porta, Camillo
    TUMORI JOURNAL, 2015, 101 (02): : 139 - 143
  • [37] Tislelizumab plus chemotherapy is an optimal option for second-line treatment for advanced gastroesophageal junction adenocarcinoma
    Yang, Ping
    Pan, Tao
    Wang, Ming-Kun
    Xiao, Meng-Sheng
    Zhang, Shuang
    Liu, Sha
    ANTI-CANCER DRUGS, 2024, 35 (07) : 666 - 671
  • [38] The Qualitative Effect of Empagliflozin as a Second-Line Treatment Option Compared with Other Oral Antidiabetic Agents
    Koutsovasilis, Anastasios G.
    Sotiropoulos, Alexios
    Pappa, Maria
    Tamvakos, Charalampos
    Christodoulopoulou, Anni
    Dermatis, Theodoros
    Kapsalakis, Georgios
    Bousboulas, Stavros
    Peppas, Theodoros
    DIABETES, 2017, 66 : A342 - A342
  • [39] Sorafenib as second-line treatment option after failure of lenvatinib in patients with unresectable hepatocellular carcinoma
    Tomonari, Tetsu
    Sato, Yasushi
    Tanaka, Hironori
    Tanaka, Takahiro
    Taniguchi, Tatsuya
    Sogabe, Msasahiro
    Okamoto, Koichi
    Miyamoto, Hiroshi
    Muguruma, Naoki
    Takayama, Tetsuji
    JGH OPEN, 2020, 4 (06): : 1135 - 1139
  • [40] Surgical debulking of gastrointestinal stromal tumors: Is it a reasonable option after second-line treatment with sunitinib?
    Pantaleo, M. A.
    Di Battista, M.
    Catena, F.
    Astorino, M.
    Saponara, M.
    Di Scioscio, V.
    Santini, D.
    Piazzi, G.
    Castellucci, P.
    Brandi, G.
    Biasco, G.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2008, 134 (05) : 625 - 630